Parkwood LLC’s AbCellera Biologics ABCL Stock Holding History

Parkwood LLC’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-32,357	Closed	-$96K	–	86
2024 Q2	$96K	Buy	32,357 +10,824	+50%	+$41K	0.01%	119
2024 Q1	$98K	Buy	+21,533	New	+$110K	0.01%	173

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Parkwood LLC's ABCL Position: Q3 2024 in Review

Parkwood LLC sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 32,357 shares — an estimated $96K sold.

Parkwood LLC first reported a position in ABCL in Q1 2024 and held it in 2 quarters. The position peaked at $98K in Q1 2024. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Parkwood LLC reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
Parkwood LLC sold 32,357 AbCellera Biologics shares in Q3 2024, an estimated $96K.
Parkwood LLC first reported a position in AbCellera Biologics in Q1 2024 and held it in 2 quarters.
Parkwood LLC's AbCellera Biologics position peaked at $98K in Q1 2024.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Parkwood LLC's 13F filing for Q3 2024, filed 14 Nov 2024.